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Abstract
Background: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease among children, the
etiology of which involves a strong genetic component, but much of the underlying genetic determinants still
remain unknown. Our aim was to identify novel genetic variants that predispose to JIA.
Methods: We performed a genome-wide association study (GWAS) and replication in a total of 1166 JIA cases and
9500 unrelated controls of European ancestry. Correlation of SNP genotype and gene expression was investigated.
Then we conducted targeted resequencing of a candidate locus, among a subset of 480 cases and 480 controls.
SUM test was performed to evaluate the association of the identified rare functional variants.
Results: The CXCR4 locus on 2q22.1 was found to be significantly associated with JIA, peaking at SNP rs953387.
However, this result is subjected to subpopulation stratification within the subjects of European ancestry. After
adjusting for principal components, nominal significant association remained (p < 10−4). Because of its interesting
known function in immune regulation, we carried out further analyses to assess its relationship with JIA. Expression of
CXCR4 was correlated with CXCR4 rs953387 genotypes in lymphoblastoid cell lines (p = 0.014) and T-cells (p = 0.0054). In
addition, rare non-synonymous and stop-gain sequence variants in CXCR4, putatively damaging for CXCR4 function,
were significantly enriched in JIA cases (p = 0.015).
Conclusion: Our results suggest the association of CXCR4 variants with JIA, implicating that this gene may be involved
in the pathogenesis of autoimmune disease. However, because this locus is subjected to population stratification
within the subjects of European ancestry, additional replication is still necessary for this locus to be considered a true
risk locus for JIA. This cell-surface chemokine receptor has already been targeted in other diseases and may serve as a
tractable therapeutic target for a specific subset of pediatric arthritis patients with additional replication and functional
validation of the locus.
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Background
Pediatric arthritis is the leading cause of acquired dis-
ability in children, afflicting about one in 1000 children
worldwide [1, 2], all ethnicities and both genders, with
onset as early as the first year of life. Classification
schemes for pediatric arthritis are under evolution, akin
to the recent classification changes for adult rheumatoid
arthritis [3]; juvenile rheumatoid arthritis (JRA) is the
term used historically in North America, while juvenile
idiopathic arthritis (JIA) is the preferred name else-
where, and is now used increasingly worldwide. JIA is
defined as a group of chronic arthritides of unknown eti-
ology, occurring in children from 0 to 16 years of age
[4]. Morbidity associated with JIA can be life-long – with
as many as 50 % of children with JIA entering adulthood
with active disease [1, 2] – and represents a significant
medical, financial, and emotional burden for patients,
their families, and society. In the United States alone,
arthritis and rheumatic diseases impact more than 46
million adults and 300,000 children, at a cost of $128 bil-
lion annually in direct and indirect medical costs [5–7].
Adults with JIA have lower rates of employment than
matched controls, and health-related quality of life is di-
minished in adults with JIA, particularly in those with ac-
tive disease [8]. Prompt recognition of the disease is
important in preventing permanent disability; however,
lack of specific confirmatory testing often delays diagnosis.
The optimal management of JIA remains complicated and
poorly defined, despite recent advances in therapy [1, 2].
The etiology of JIA is largely unknown. To our know-
ledge, there are no data supporting a major role for en-
vironmental exposures [9]. This does not preclude a role
of the environment in the pathogenesis of JIA, but re-
search to identify environmental risk factors is lacking.
On the other hand, strong contribution of genetic com-
ponents has been implicated from twin to family studies
[10]: monozygotic twins have a concordance rate be-
tween 25 and 40 %; the calculated sibling recurrence risk
ratio (λs = 15–30) is similar to that calculated for type 1
diabetes. Sibling pairs tend to show concordance for age
of onset, subtype and course; and a subset of patients
with JIA exhibits a heritable predisposition to develop
this disease with an autosomal dominant pattern of
inheritance.
Yet, in comparison to other autoimmune diseases of
similar prevalence, the genetic etiology of JIA remains
largely elusive. The major histocompatibility complex
(MHC), in particular, the HLA-DRB1 locus, has been
established as having the strongest influence on suscepti-
bility to JIA [11], contributing ~20 % of the proportion
of sibling recurrent risk [12]. Non-MHC loci are import-
ant as well, with 16 loci now associated with JIA at
genome-wide significance. Fourteen of these were identi-
fied for the first time by a recent Immunochip analysis
[13], a hypothesis-driven approach that focused upon
genes with known associations with immune disorders
[14]. To comprehensively search for genes related to JIA
and given that the pathophysiological mechanisms
underlying JIA are unknown, we took an unbiased ap-
proach of genome-wide association study (GWAS) and
performed replication studies in independent cohorts,
including a total of 1166 cases and 9500 controls after
quality control (QC) filtering. We subsequently per-
formed targeted resequencing at identified candidate
locus of CXCR4 gene among a subset of 480 cases and
490 controls. Here we report that variants in gene
CXCR4 associate with JIA.
Methods
Participants
The JIA cases in our study were recruited from five sites
in USA, Australia, and Norway: Texas Scottish Rite Hos-
pital for Children (TSRHC; Dallas, Texas), Children’s
Mercy Hospitals and Clinics (CMHC; Kansas City, Mis-
souri), the Children's Hospital of Philadelphia (CHOP;
Philadelphia, Pennsylvania), the Murdoch Childrens Re-
search Institute (MCRI; Royal Children’s Hospital, Mel-
bourne, Australia), and Oslo University Hospital (OUH;
Oslo, Norway). (Table 1, Additional file 1: Table S1). A
subset of subjects from these sites has been described
previously [15–19]. JIA diagnosis was made according to
the International League of Associations for Rheumatol-
ogy (ILAR) revised criteria [4] and confirmed using the
JIA CalculatorTM software (URLs) [20], an algorithm-
based tool adapted from the ILAR criteria. All JIA cases
were of age of onset <16 years old.
The clinical data of JIA case in the CHOP cohort were
collected from the JIA Registry maintained within the
CHOP Division of Rheumatology; clinical data of case
samples from TSRHC, CMHC, MCRI, and OUH were
Table 1 Demographic and clinical characteristics of our JIA
dataset
JIA SubtypesA % female Age (years)B
Oligoarthritis, persistent 73 % 5.9 (2.9,9.7)
Oligoarthritis, extended 82 % 3.95 (2.4,7.8)
Polyarthritis, RF negative 79 % 7.48 (3.2,11.3)
Polyarthritis, RF positive 95 % 13.5 (10.3,15.1)
Systemic arthritis 67 % 6.6 (3.2,11.1)
Enthesitis-related arthritis 40 % 11.9 (9.0,14.1)
Psoriatic arthritis 71 % 9.9 (7.0,13.2)
Undifferentiated arthritis 55 % 9.8 (4.5,13.8)
Total 68 % 8.3 (3.8,12.2)
ARevised ILAR criteria.
BAge (years): median (25 % percentile, 75 % percentile)
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drawn from medical records provided by the respective
sites and stored in a de-identified database at the Center
for Applied Genomics of the CHOP Research Institute.
The control subjects used are unrelated and disease-
free children recruited within the CHOP Healthcare
Network. Control subjects had no history of JIA or other
chronic illnesses and were screened as negative for a
diagnosis of autoimmune diseases, based on data from
CHOP’s electronic health record and by intake question-
naires obtained by the recruiting staff from the Center
for Applied Genomics. A total of 6500 pediatric controls
passed stringent quality control (QC) filtering, as de-
tailed below; post-QC, cases and controls were matched
based on the multidimensional scaling (MDS) analysis
[21, 22]. For OUH cohort, the 3000 well-characterized
subjects from the Wellcome Trust Case–control Consor-
tium (WTCCC) [21] were used as controls.
We combined TSRHC and CMHC samples to form
the discovery cohort, and kept CHOP, MCRI and OUH
cohorts as three independent replication cohorts.
Ethics statement
The study was approved by the institutional review
boards of TSRHC, CMHC, CHOP, MCRI, OUH, and
CCHMC, and was compliant with HIPAA regulations.
Parental written informed consent was obtained from all
participants prior to inclusion in this study for the pur-
pose of DNA collection and genotyping.
Genotyping
All samples except those in the OUH replication cohort
were genotyped using Illumina HumanHap550 Bead-
Chip or the Human610-Quad arrays. The 530,000 SNPs
that are overlapped by these two platforms were in-
cluded in the study. Samples in the OUH replication co-
hort were genotyped using the Affymetrix GeneChip
500 K Mapping Array Set.
Quality control
We employed the MDS algorithm implemented in
PLINK to infer population structure, with the 924 indi-
viduals from the HapMap project as reference. Only
samples of genetically inferred European ancestry were
kept for further analysis. We then applied QC filters to
exclude samples of poor genotyping quality prior to as-
sociation analysis. A sample was excluded if the geno-
type call rate was <95 % or if the sample showed excess
or deficient heterozygosity (inbreeding coefficient |F| >
0.1). Cryptic relatedness or erroneous duplicates were
evaluated using pair-wise identity-by-descent estimation,
and the sample with lower genotype call rate was re-
moved from each identified relative pair. In our study,
we also eliminated SNPs with genotype call rate <98 %,
with minor allele frequency (MAF) <1 % in either cases
or controls, or if there was significant departure from
Hardy-Weinberg equilibrium (p < 0.0001). In the discov-
ery cohort, a total of 518,907 genotyped SNPs passed
QC and were included in analysis.
Principal component analysis (PCA)
After the above sample and SNP QC, we conducted
principal component analysis, trying to resolve relation-
ship within-European samples. Using PLINK, we per-
formed LD pruning and SNP exclusion so that only
independent SNPs (r2 < 0.2) on the autosomes were kept
for PCA. We then performed PCA using EIGENSTRAT
[23]. MDS analysis was also performed with the inde-
pendent SNPs using PLINK.
Association analyses
For genotyped SNPs, association was tested by basic al-
lelic test (chi-square test) and the odds ratio was calcu-
lated with respect to the minor allele using PLINK [22].
Logistic regression analyses were additionally performed,
including the first 10 coordinates from the MDS analysis
as covariates. Similar analyses were also performed in-
cluding the first 10 principal components from the PCA
analysis as covariates. Conditional association analysis
was performed by including the genotype of the most
associated SNP rs953387 as a covariate.
Imputation
Imputation was carried out using software MACH 1.0
[24], with the reference panel of the HapMap CEU sam-
ples (HapMap release 22, NCBI build 36). The default
two-step procedure was adopted for imputation. Im-
puted SNPs with MAF <0.01 in either cases or controls
and SNPs with poor imputation quality (r2 < 0.3) were
excluded from further analysis. We also zeroed out im-
puted genotypes with a posterior probability of <0.9.
Meta-analysis
We performed meta-analysis using the inverse variance
based method implemented in software METAL [25],
which accounts for the direction of association relative
to a consistent reference allele and adopts a fixed effect
model. In this method, the effect size estimate of each
cohort is weighted by its corresponding standard error.
All meta-analyses comply with MOOSE guidelines
(URLs).
Targeted resequencing
We selected 480 patients with JIA and 480 controls
without history of any autoimmune or inflammatory dis-
eases, all of European ancestry based on the above MDS
analysis. Samples were pooled in batches of 8 cases or 8
controls. One control pool was excluded for final ana-
lysis because it failed QC. Library preparation for
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targeted resequencing was performed according to the
TruSeq (Illumina) sample-preparation protocol. DNA li-
braries were then hybridized to customized probes for
capturing CXCR4 with NimbleGen SeqCap EZ Choice
Library (Roche NimbleGen). The captured region is
chr2:136871907–136895725, including introns. CXCR4-
enriched libraries were sequenced on the HiSeq 2000
(Illumina).
We performed sequence alignment using BWA against
the reference human genome (UCSC hg19). We
achieved ~320X coverage per pool or ~40X per individ-
ual. We performed variant calling using SNVer [26], a
statistical tool designed for pooled sequencing data. We
used ANNOVAR software [27] to annotate variants.
Each pool has 2 × 8 = 16 haplotypes, so we estimated al-
lele frequency by rounding X/K*16, where X is the num-
ber of reads carrying the alternative allele, and K is the
total coverage.
Statistical analysis for targeted sequencing
For the sequencing data, we employed the SUM test
[28] for testing the association of the identified multiple
non-synonymous variants. We computed the SUM asso-
ciation p value using the R package AssotesteR. Specific-
ally, we used a permutation version of SUM, in order to
prevent an inflated Type I error.
Sanger sequencing
We performed Sanger sequencing to validate the rare
non-synonymous and stop-gain sequence variants iden-
tified by targeted resequencing. Primers for all the five
variants were designed using software Primer3 [29, 30]
(URLs). Purification of PCR products was conducted
using ExoSAP-it (USB, Affymetrix), and Sanger sequen-
cing on both strands was performed using Big Dye Ter-
minator Cycle Sequencing Kit v3.1 Kit (Applied
Biosystems) with ABI 3130xl Genetic Analyzer (Applied
Biosystems).
eQTL analyses
To test association between SNP genotypes and gene ex-
pression quantified in immortalized B-lymphocytes and
T-cells, we performed in silico analysis using publicly
available data from genome-wide expression analysis of
quantitative trait loci (eQTL) of the 270 individuals ge-
notyped in the HapMap Project (including 30 Caucasian
trios of Northern and Western European origin [CEU])
[31–34] and the 85 individuals of the GenCord project
(a collection of cell lines from umbilical cords of individ-
uals of Western European origin) [35]. Linear regression
was used to test the association between gene expression
and SNP genotypes under additive model [32]. SNP
genotype was coded as 0, 1, and 2, corresponding to the
counts of the minor allele in each genotype.
Results
Replication of known JIA susceptibility loci
We performed a genome-wide association study in the
discovery cohort (TSRHC + CMHC) including 388 chil-
dren with JIA and 2500 genetically matched controls of
European ancestry with high-quality SNP array data
(Table 1, Additional file 1: Table S1). Then three inde-
pendent JIA cohorts (CHOP, MCRI, OUH) were ana-
lyzed for replication and followed by meta-analysis of all
the cohorts in a total of 1166 cases and 9500 controls
(Table 1, Additional file 1: Table S1). The age at onset,
gender, and subtype distributions of all case cohorts are
similar to those reported previously for JIA [1].
We focused on the phenotypic commonality amongst
our patients, that is, chronic inflammation of the joints.
We observed a strong genome-wide significant associ-
ation at the HLA locus on 6p21 (Additional file 1: Table
S2, Additional file 1: Figure S1), A total of 24 SNPs sur-
passed genome-wide significance threshold at this region
in the discovery cohort. Furthermore, three loci which
previously have been implicated in JIA and several other
autoimmune diseases [10, 36, 37] – the PTPN22 locus
on 1p13, the IL2RA locus on 10p15, and the ANTXR2
locus on 4q21.21 – were nominally associated with JIA
(Additional file 1: Table S3). Replication of these known
JIA susceptibility loci demonstrated the validity of our
study.
Novel association of CXCR4 common variants
In addition to these known loci, we found a novel associ-
ation signal at 2q22.1, with the most significant marker be-
ing rs953387 (p = 2.07 × 10−10; OR 0.59, 95 % CI 0.50–
0.69). Six genotyped SNPs and ten additional imputed SNPs
located on 2q22.1 of p value < 5 × 10−8 (Additional file 1:
Table S4–S5, Additional file 1: Figure S1–S2) in the discov-
ery cohort. Conditional on the top SNP rs953387, the sig-
nificant association of the other SNPs were ablated,
suggesting a single association signal at this locus. These
SNPs were all nominally significant in each of our three in-
dependent replication cohorts. (Additional file 1: Table S4).
Combined meta-analysis of all four cohorts indicated that
four SNPs at the 2q22.1 locus were of p values < 5 × 10−8
(Additional file 1: Table S4).
However, as CXCR4 is near a known stratified locus
(nearby the lactase gene) [38], logistic regression analysis
including the first ten coordinates from the MDS ana-
lysis as covariates brought the locus p value below
genome-wide significance (top associated SNP
rs1016269, P = 4.70 × 10−5). Similarly, using the first 10
principal components as the covariates in the logistic re-
gion association, we obtained similar results (top associ-
ated SNP rs1016269, P = 2.80 × 10−5). Thus, our original
association results were inflated due to subpopulation
stratification within the subjects of European ancestry.
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The association of CXCR4 was nominally significant
with the best p-value <0.0001. When we evaluated the
association by another method, permutation tests with
the inclusion of the first ten coordinates from the MDS
analysis as covariates in each association analysis, we ob-
tained similar results of nominally significant results
based on 10,000 permutations. CXCR4 is an interesting
gene because of its known role in immune regulation in
a variety of immune cell types as a chemokine receptor.
Gene CXCR4, is expressed on the surface of T-cells,
B-cells, monocytes, neutrophils and dendritic cells
(Additional file 1: Figure S3). The important function of
CXCR4 during B cell development and activation [39, 40],
and the key role of B cells in pathogenesis of JIA [41]
make CXCR4 an intriguing target worth of further exam-
ination. Because of sub-population stratification, add-
itional replication is still necessary for this locus to be
considered a true risk locus for JIA. Its association with
JIA need to be further investigated by stratified analysis in
more refined homogeneous sub-populations of European
ancestry, with a larger sample size. Further functional
studies would also be required to demonstrate its potential
contribution to JIA etiology.
Correlation between SNP genotype and CXCR4 expression
Additionally, rs953387 was significantly associated with
the mRNA levels of CXCR4 (p = 0.014; Additional file 1:
Figure S4) among HapMap dataset of 30 CEU children in
the Sanger Institute GENe Expression VARiation (Gene-
var) public database (URLs), which profiles gene expres-
sion in immortalized B-lymphocyte samples [31]. Analysis
of an independent dataset of T-cell lines from umbilical
cords of 75 individuals of Western European origin [35]
also demonstrated association between genotypes of
another significant SNP rs1016269 at CXCR4 locus
(Additional file 1: Table S5) and levels of CXCR4 expression
(p = 0.0054; Additional file 1: Figure S3). These data suggest
that common variants at CXCR4 locus may regulate mRNA
expression of this chemokine receptor.
Novel association of CXCR4 rare variants
In addition to common variants, rare variants also con-
tribute to disease susceptibity and usually confer a larger
effect than common variants. We further examined rare
variants at this locus by conducting deep resequencing
in 480 JIA cases and 480 controls. Table 2 shows the
variants identified in the coding region of CXCR4. Of
interest are 4 non-synonymous and 1 stop-gain SNVs.
These are all rare variants that are not catalogued in
current variant databases (1000G and ESP6500) or with
an extreme low frequency (0.0003). Four of these five
rare variants are present only in JIA patients, not in con-
trols. The SUM test produced a significance p value of
0.015 when testing the association of these 5 variants,
suggesting that rare variants in the CXCR4 gene may be
contributing to the pathogenesis of JIA.
Then we performed Sanger sequencing to validate their
genotype status. The primer sequences for each rare vari-
ant are shown in Additional file 1: Table S6. Among 40
samples of the 5 pools from which the rare variants were
detected, 33 samples were left with enough DNA for
Sanger sequencing. No genomic DNA was left for 4 sam-
ples in pool from which variant chr2:136872970 was iden-
tified and 3 samples in pool from which variant chr2:
136873341 was found. Among the 33 samples with
enough genomic DNA, 4 samples were found carrying the
rare variant identified in deep sequencing (Fig. 1).
Discussion
In a combined sample set of more than 1100 JIA sub-
jects of European ancestry, we replicated common
Table 2 Summary of variants in CXCR4 coding-region by deep resequencing
Chr Pos Ref Obs Exonic Function ESP6500 1000G dbSNP135 CASE Freq. CTRL Freq.
chr2 136872553 G A synonymous SNV 0.000461 0.0014 rs144110709 0 1
chr2 136872565 G C synonymous SNV 0 1
chr2 136872705 T C nonsynonymous SNV 0 1
chr2 136872715 G A synonymous SNV 0.003306 0.0018 rs148279552 3 7
chr2 136872727 A G synonymous SNV 0.000077 rs146627075 1 0
chr2 136872970 G T nonsynonymous SNV 1 0
chr2 136873084 G A synonymous SNV 0.036983 0.06 rs2228014 40 41
chr2 136873341 T G nonsynonymous SNV 0.000308 rs56400844 2 0
chr2 136873491 G C nonsynonymous SNV 1 0
chr2 136873496 A T stopgain SNV 1 0
Chr chromosome, Pos position on human genome build hg19, Ref reference allele, Obs the variant allele observed in our JIA dataset, ESP6500 variant allele
frequency in Exome Sequencing Project, 1000G variant allele frequency in Thousand Genome Project, dbSNP 135 SNP rs ID in Single Nucleotide Polymorphism
database of human genome build 135, CASE Freq variant allele frequency among cases, CTRL freq variant allele frequency among controls
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genetic variants at loci of HLA, PTPN22, IL2RA and
ANTXR2 that have been reported for association with
susceptibility to JIA. We also found a nominally signifi-
cant association at CXCR4 which has been implicated in
immune regulation, demonstrated the correlation be-
tween CXCR4 variants genotype and its gene expression
level. We further showed that rare non-synonymous and
stop-gain variants in CXCR4 are enriched in JIA cases.
Our data support a role for altered expression of CXCR4
in JIA pathogenesis, and present the first genetic demon-
stration of a potential role for the chemokine receptor,
CXCR4, in the pathogenesis of autoimmune disease. Be-
cause this locus is subjected to population stratification
within the subjects of European ancestry, additional rep-
lication is still necessary for this locus to be considered a
true risk locus for JIA.
Few genetic studies of JIA have been carried out at
genome-wide scale. Previously reported GWASs of JIA
were all limited by small size [42, 43]. A more recent study
using Immunochip, took a hypothesis-driven approach,
targeting immune-specific genes. Several significant new
loci were identified from the study [13], however the
Immunochip does not capture variants across a large pro-
portion of the genome. Our study was composed of a
large dataset with comprehensive genome SNP coverage,
and the candidate gene identified was examined using tar-
geted resequencing with a large number of samples and
high coverage.
Chemokine receptors impact immune system develop-
ment and function in part via regulation of cell migration.
The G protein-coupled chemokine receptor, CXCR4, is
expressed on the surface of T-cells, B-cells, monocytes,
neutrophils and dendritic cells (Additional file 1: Figure
S3), and is activated exclusively by CXCL12 (also known
as stromal-derived-factor-1, SDF-1), a small peptide medi-
ator and potent chemoattractant for leukocytes, including
B- and T-cells. CXCR4 and its ligand, CXCL12, have been
shown to play a role in B-cell production, myelopoiesis,
integrin activation, angiogenesis, and chemotaxis [25]. In-
triguingly, the human immunodeficiency virus (HIV-1)
has usurped CXCR4’s unique CXCL12 binding site,
exploiting CXCR4 as a co-receptor in later stages of HIV-
1 infection, and CXCR4 antagonists have been explored as
treatments for HIV infection. Binding of CXCR4 to
CXCL12 is also proposed to play a role in cancer metasta-
ses, and CXCR4 antagonists are under study in human
clinical trials for solid and non-solid tumors [44]. Available
therapeutic agents targeting the CXCR4-CXCL12 axis for
activation or inhibition include plerixafor (AMD3100), re-
combinant CXCL12, and high-affinity CXCR4 and
CXCL12 monoclonal antibodies, some of which are
already in use in the clinic but not approved for use in
children. The recent report of crystal structures of CXCR4
with small-molecule and cyclic peptide inhibitors [45]
provide new opportunities for drug discovery efforts tar-
geting this receptor.
Fig. 1 Sanger validation of rare variants in gene CXCR4. The sequencing chromatograms are shown for the sample carrying the rare variant allele
and a representative control that does not have the rare variant allele. a chr2:136872705; b chr2:136873341; c chr2:136873491; d chr2:136873496.
The rare variants are highlighted in the figure
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CXCR4 and CXCL12 have been implicated in the patho-
genesis of autoimmune diseases [44, 46]. In mouse models
of autoimmune disease, modulation of CXCR4 alters traf-
ficking of leukocytes to peripheral organs and polarization
of regulatory T cells, and accelerates onset of disease [47,
48]. This is consistent with our data showing that a risk
variant of CXCR4 correlates with decreased expression of
CXCR4. An alternate hypothesis is that the effect of low
CXCR4 expression is indirect and leads to a compensatory
increase of the CXCR4 ligand, CXCL12. Our preliminary
data suggest that the risk variant of CXCR4 correlates with
increased expression of CXCL12 (data not shown). This is
consistent with models of collagen-induced arthritis in
which CXCL12 acts as a pro-inflammatory factor in the
pathogenesis of inflammatory arthritis [49, 50], and with
human studies in which CXCL12 enhances cellular prolif-
eration and cytokine expression by peripheral blood T
cells, upregulates expression of cytokines and chemokines
by fibroblast-like synoviocytes from patients with RA [51],
and mediates lymphocyte ingress into RA synovial
tissue, synovial neovascularisation, and osteoclastogen-
esis [52]. Translation of our discovery into therapeutic
benefit for a specific group of JIA patients will re-
quire additional genetic replication studies, proper
functional validation and greater insight into the
pathogenic role of CXCR4 in JIA.
Conclusions
We uncovered common SNPs at the CXCR4 locus
associated with JIA and further found rare functional
variants at CXCR4 enriched in JIA cases. Our results
suggest that genetic variants at the CXCR4 locus
may predispose to the development of JIA. Because
of sub-population stratification, additional replication
is still necessary for this locus to be considered a
true risk locus for JIA. The extensive literature sur-
rounding the biology of CXCR4 and its binding part-
ner CXCL12 in health and disease, and the ready
availability of targeted therapeutic agents make
CXCR4 a particularly attractive candidate for further
genetic replication and functional investigation of its
pathogenic role and therapeutic potential in JIA and
other autoimmune diseases affecting children.
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